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Abstract
Background: The proposed Pharmacy Bill of Malaysia which served to consolidate and harmonise the existing
pharmacy legislation which has been used for more than 60 years. This new Pharmacy Bill contains 17 parts and a
total of 170 legislative sections covering laws governing pharmacy practice, medicinal products classification,
registration, sale, supply, licensing etc. Our article could serve as a case study on pharmacy jurisprudence and drug
regulation as well as the governance for medicines.
Discussion: Changes to the colonial era legislation are long overdue as the present pharmaceutical and medical
controls are not integrated and various overlaps exist in terms of roles of control. However, various organisations of
private general practitioners strongly opposed this Pharmacy Bill and lobbied for a revised version that greatly
favours themselves. Thus, the latest revision of this Pharmacy Bill renders the power to medical doctors to not only
continue selling and supplying medications but also compound medication.
Summary: A complete overhaul of pharmacy legislation in view of the current challenges faced in providing
efficient and comprehensive health services in Malaysia is necessary. For the sake of patients’ safety and good
governance for medicines, the private general practitioners should empower the patients with their needs for
prescription and itemised billing. The proposed Pharmacy Bill could make the whole mechanism of managing and
controlling the use of medicines more transparent and synchronised.
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Background
A New Pharmacy Bill (NPB) is expected to be tabled
in the Malaysian Parliament this year after obtaining
approval from the Attorney General. The current pharmacy
legislation is made up of separate acts, namely the Poisons
Act (1952), Sale of Drugs Act (1952), Registration of
Pharmacists Act (1951) and the Medicines (Advertisement
and Sale) Act (1956) [1]. The consolidation of these
pre-independence laws into the NPB is expected to
address lacunae in the existing legislation and safeguard
public health and safety by harmonising the classification
of drugs, and providing stronger deterrent penalties for
offences regarding counterfeit medicinal products, psy-
chotropic distribution and the diversion of precursor
chemicals [2]. Notwithstanding this, the proposed NPB
has been strongly opposed by the various medical associa-
tions and federations in Malaysia on the grounds that pro-
visions in the legislation have the potential to deprive
doctors of the legal right to sell and supply medicine to
patients [3, 4]. In our view, this negative reaction is mainly
due to a misinterpretation of the draft content, and that,
in reality, the NPB does not include any terms on dispens-
ing separation.
To formalise the discussion, Federation of Private
Medical Associations Malaysia organised a National Forum
on the NPB and Relevant Laws, held in April 2015. Subse-
quently, 17 associations, mainly representing private med-
ical practitioners from various states in Malaysia, presented
a joint memorandum to request the Health Ministry to
cancel numerous laws that were deemed disadvantageous
to their practice. On a similar note, the Malaysian Medical
Association rejected the NPB, complaining that relevant
stakeholders had not been consulted, and that the bill had
been brought forward without proper consideration of the
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privileges of these stakeholders, especially in respect to the
sale and supply of medicine by doctors.
Are we reversing health care system back to colonial era?
The Poisons Act currently regulates the importation,
possession, manufacturing, compounding, storage, trans-
portation, sale and use of poisons by doctors, dentists,
veterinarians, manufacturers, distributors and retail stores.
At present, scheduled poisons (in layman’s term medi-
cines), according to the Poisons Act, are mainly grouped
as Groups A, B and C poisons, as well as psychotropic
drugs/substances (drug that changes brain function and
alter perception, mood and consciousness). Under this
classification system, Group A poisons cannot be used in
humans, but only for trade or scientific research purposes.
Group B poisons and psychotropic drugs can be supplied
with a prescription by a physician, dentist, veterinarian
or pharmacist; while Group C poisons can be supplied
without a prescription by a pharmacist holding a valid
practising license. In the proposed NPB, poisons will be
categorised into three categories, namely prescription
only medicines (POM), pharmacy medicines (PM) and
general sales list medicines (GSL).
 POMs cover psychotropic and narcotic medical
products, and medical products formerly classified
as Group B poisons that required a prescription to
be supplied.
 PMs can be obtained from licensed pharmacists
without a prescription. These consist of
psychotropically active substances and precursors
formerly in the Group B and C poison categories.
PMs also include finished products containing
drugs such as antihistamine, pholcodine,
antidiabetics, and external preparations
containing an antibiotic or steroid.
 GSL consists of registered products such as
traditional medicines or supplements or cosmetics
which are available over-the-counter.
Advocates of the proposed NPB hailed the reclassifica-
tion of medicines as necessary and timely since the current
scheduled poison system is confusing and outdated. The
general public does not understand and know the differ-
ences between medicines in Group B and C. Unintention-
ally, patients sometimes request Group B medicines from a
pharmacy without a proper prescription. With the new
classification of PM, a clear label of “pharmacy medicine”
could be printed on the product packaging to indicate that
the medicine in question could be supplied by a licensed
pharmacist.
The proposed classification is not uncommon, with the
United Kingdom, Singapore and many other countries
having adopting such a system. It provides a clearer
description of the medicines group and the basis on which
these can be supplied to patients. Some medicines are in
dire need of reclassification since inappropriate or out-
dated classifications are currently restricting the availabil-
ity and affordability of these medicines. For instance, the
Singapore Health Sciences Authority, in October 2015,
declassified cetirizine (an antihistamine to treat flu and
allergic reactions) from PM to GSL [5], while in Malaysia,
it remains classified as a Group C poison, only to be sold
by a pharmacist. The reclassification of active psycho-
tropic substances and precursors formerly in the Group B
poison category to the PM group has also been grossly
misinterpreted by certain medical associations [3], who
argue that psychotropic drugs will now be classified PM,
whereas currently doctors are allowed to sell and supply
psychotropic drugs without screening by a pharmacist. It
must be highlighted that active psychotropic substances
and precursors are actually the raw active pharmaceutical
ingredients (raw powder) of psychotropic drugs that are
used in the manufacturing of pharmaceutical dosage
forms (tablets, capsule and syrup) or for import or export
purposes. Under the NPB, doctors are still allowed to sale
and supple psychotropic drugs such as buprenorphine
tablet or methadone syrup.
This oversight led to a joint memorandum being pro-
posed in respect to the NPB by various medical and
dental organisations, arguing that the new classification
of “Pharmacist Medicines” will result in an effective
monopoly being created on behalf of pharmacists in re-
spect to the supply of medicines, and including psycho-
tropic drugs that are currently listed as Group B poisons
[3]. A further concerned expressed in the joint memoran-
dum is that the Senior Director of Pharmaceutical Ser-
vices is viewed as having a free hand to classify medicines
based on profession, effectively taking away, or severely
curtailing, the dispensing role of medical practitioner,
dental practitioners and veterinary surgeons in private
facilities. Reluctant to countenance any changes, oppo-
nents of the NPB are insisting on maintaining status
quo in pharmacy legislation, arguing that the existing
system is a proven affordable and convenient system of
care since the doctors could provide diagnosis and
medication independently.
From another viewpoint, the Secretary General of the
Malaysian Consumers’ Association has stressed the im-
portance of empowering consumers with choices so they
can make the best decisions according to their needs. The
concern is not who dispenses the medicine but whether
the patients are getting the maximum benefits from the
changes in legislation. Medication consultation and
screening performed by pharmacists not only minimise
the prescription error but also ensure patients are coun-
selled correctly in term of potential drug interactions and
dosing. Another worrying trend seem in Malaysia is
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private medical practitioners tend to prescribe seven times
more medicines which might not be essential for the pa-
tient’s condition [6]. Over-prescribing of non-essential
medication will further burden the patient and jeopardize
patient’s safety since number of medication prescribed is a
predictor for medication error [7].
Dispensing doctors lead to uncontrolled medication
prices?
Another concern often raised by public is non-itemised
billing by the general practitioner (GP) and private hos-
pitals. The associations of general practitioner tend to
cite the reason that GP compensate the consultation fees
on the medicine prices. This ambiguous charging system
might not be suitable now because generic medicines
are widely available now. A generic medicine could easily
cost 3–6 times less than the innovator product. For ex-
ample a box (30 tablets) of generic losartan tablet for
treatment of hypertension could cost MYR 15 (equivalent
to USD 3.75) (USD 1 ≈MYR 4, IMF 2016) [8] compare to
the innovator of MYR 83.40 (USD 20.85). Furthermore, a
box (30 tablets) of generic clopidogrel tablet for blood
thinning could cost RM 70 (USD 17.50) compare to the
innovator (14 tablets) of RM 90 (USD 22.50). Tested and
proven health care financing system in countries such as
Korea, Australia and Taiwan have switched to pharmacy
dispensing to facilitate medicine pricing regulation. Com-
ing back to Malaysia scenario, currently there are no rele-
vant laws that give authority to the pharmacy enforcement
officer to control drug prices sold in this country. In order
to curb unregulated medicine pricing in private sector, the
Health Minister stated that the proposed NPB would
include legitimate mechanisms for medicine pricing
regulation. The effort to regulate medicine prices is a step
in the right direction since there is currently a lack of
transparency in pharmaceutical supply chains. Price dis-
parities exist within and between distribution channels.
Unfair bonuses, discounts and rebates are examples of the
tactics employed by pharmaceutical companies to distort
demand, thus creating an unhealthy and dysfunctional
market and business environment. GPs, as the primary
initiators for pharmaceutical demand, are given better
prices compared to private pharmacies. Although prevent-
ive measure have been taken by the Malaysia’s Ministry of
Health issuing a Guideline on Good Pharmaceutical Trade
Practice, its effectiveness is doubtful as it has no legally
binding [9]. It must be highlighted that a lower cost price
given to GPs has not translated into a cheaper drug price
as the patients are still charged the recommended retail
price. Therefore, pharmacy is considered as the preferred
choice for the treatment of minor ailments whereby a pa-
tient could purchase two to three types of medicines with
approximately RM10 (USD 2.50) in a pharmacy as com-
pared to more than RM40 (USD 10) in a GP clinic.
Conclusions
Changes to the colonial era legislation are long overdue as
the present pharmaceutical and medical controls are not
integrated and various overlaps exist in terms of roles of
control. These changes could make the whole mechanism
of managing and controlling the use of medicines more
transparent and synchronised. The work on the proposed
NPB has been on the drawing board for the past 20 years,
and the time is now right for a complete overhaul of
pharmacy legislation in view of the current challenges
faced in providing efficient and comprehensive health
services in Malaysia.
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